How Florida Cancer Specialists contributed to a study that may change KRAS G12D cancer treatment
Setidegrasib showed early activity in KRAS G12D lung and pancreatic cancers. Read why the Phase 1 signal could matter for oncology’s next target.
Dizal’s Zegfrovy challenges chemo dominance in rare EGFR lung cancer mutation
Zegfrovy Phase 3 results could redefine EGFR exon20ins lung cancer treatment. Discover what this means for frontline therapy and future care strategies.
Could IDEAYA Biosciences challenge current standards in metastatic uveal melanoma with darovasertib?
IDEAYA Biosciences nears darovasertib trial data. Discover how results could reshape metastatic uveal melanoma treatment strategies.
PAQ Therapeutics initiates Phase 1 for PT0511 pan-KRAS degrader, raises $77m in Series B
PAQ Therapeutics begins Phase 1 trial for PT0511 pan-KRAS degrader and raises $77M. Find out what this means for the future of KRAS-targeted cancer therapy.
Pfizer’s BRAFTOVI triplet shows 64% response in first-line BRAF-mutant colorectal cancer
Pfizer’s BRAFTOVI triplet hit a 64% response rate in BRAF-mutant colorectal cancer. Find out what this could mean for first-line treatment standards.
J&J’s amivantamab shows strong first-line response in metastatic colorectal cancer
Johnson & Johnson (J&J) has reported updated results from its Phase 1b/2 OrigAMI-1 trial evaluating amivantamab-vmjw in combination with chemotherapy for patients with RAS/BRAF wild-type metastatic colorectal cancer. The bispecific antibody, which targets epidermal growth factor receptor (EGFR) and MET, achieved confirmed response rates of 73 percent in the first-line setting and 44 percent in […]
Amgen acquires Dark Blue Therapeutics to expand targeted AML degradation strategy
Amgen has acquired United Kingdom-based Dark Blue Therapeutics Ltd. in a deal valued at up to $840 million, adding a first-in-class preclinical asset to its early oncology pipeline. The investigational small molecule, designed to degrade MLLT1 and MLLT3 proteins, targets transcriptional dependencies in acute myeloid leukemia. With preclinical data suggesting anti-leukemic activity and mechanistic differentiation, […]
Curasight begins Phase 1 trial of uTREAT in glioblastoma, marking shift to clinical-stage radiopharma development
Curasight A/S has dosed the first patient in a Phase 1 clinical trial of uTREAT for glioblastoma, launching the therapeutic half of its uPAR-targeting theranostic platform alongside its companion diagnostic, uTRACE, which is already in Phase 2 for prostate cancer. How curative ambitions shift when a theranostic platform enters human testing in glioblastoma Curasight’s advancement […]
Can Johnson & Johnson’s RIPTAC bet deliver the next wave of targeted oral cancer drugs?
Johnson & Johnson’s $3B Halda acquisition brings RIPTACs into focus. Find out what it means for prostate cancer therapy and precision oncology.
Why Verastem Oncology’s KRAS G12C trial exit reveals a calculated pivot to next-generation lung cancer targets
Verastem exits its G12C lung cancer trial to prioritize VS-7375, a next-gen G12D inhibitor showing promise. Find out how this pivot could change KRAS therapy.